GlassScriptPhysician profile
Dana L Mcdaniel
NPI 1295792547
$1,363.67
in general payments reported to CMS, 2019-2025
32 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.13 · 2022: $20.78 · 2023: $235 · 2024: $749 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.97 |
| Education | $291.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $291.79 | 2024 | |
| Abbvie INC. | $187.12 | 2024-2025 | |
| Pfizer INC. | $73.74 | 2024-2025 | |
| Emd Serono, INC. | $71.26 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $66.67 | 2023-2024 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $59.64 | 2023-2025 | Opdivo, Opdualag |
| Aveo Pharmaceuticals, INC. | $52.92 | 2023-2025 | Fotivda |
| Exelixis INC. | $49.08 | 2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $45.88 | 2023-2024 | |
| Genzyme Corporation | $36.34 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $32.78 | 2023-2025 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $28.13 | 2023 | Epkinly |
| Ferring Pharmaceuticals INC. | $24.95 | 2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $23.68 | 2023 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $22.13 | 2024 | Onivyde |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Masimo Corporation | $20.78 | 2022 | |
| Coherus Oncology, INC. | $20.68 | 2023 | |
| Myriad Genetic Laboratories, INC. | $20.16 | 2024 | Myrisk |
| Janssen Biotech, INC. | $20.09 | 2025 | Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $19.60 | 2024 | Fruzaqla |
| Argenx US, INC. | $19.35 | 2024 | Vyvgart Hytrulo |
| Glaxosmithkline, LLC. | $18.66 | 2024 | Ojjaara |
| Seagen INC. | $18.55 | 2023 | Tukysa |
| Incyte Corporation | $17.85 | 2025 | Monjuvi |
| Servier Pharmaceuticals LLC | $16.46 | 2025 | |
| Iovance Biotherapeutics, INC. | $16.40 | 2025 | Amtagvi |
| Stemline Therapeutics INC. | $16.18 | 2024 | Orserdu |
| Celgene Corporation | $15.55 | 2024 | Reblozyl |
| Boston Scientific Corporation | $15.13 | 2021 | |
| Puma Biotechnology, INC. | $14.36 | 2023 | |
| Genentech USA, INC. | $14.08 | 2023 | Columvi, Polivy, Lunsumio |
| Novocure INC. | $13.68 | 2025 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.